The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis - A pilot study

Rheumatology International

Volumn 25, Issue 6, 2005, Pages 481-484

  Omdal, Roald ^a   Gunnarsson, Ragnar ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anakinra; Fatigue; Rheumatoid arthritis; Treatment

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MUSCLE FATIGUE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SYMPTOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-1; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; TREATMENT OUTCOME;

EID: 23944450686     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0463-z     Document Type: Article

References (28)

1. Wolfe F, Hawley DJ, Wilson K (1996) The prevalence and meaning of fatigue in rheumatic diseases. J Rheumatol 23:1407-1417
2. Koike T, Kazuma K, Kawamura S (2000) The relationship between fatigue, coping behavior, and inflammation in patients with rheumatoid arthritis. Mod Rheumatol 10:141-149
3. Krupp LB, LaRocca NG, Muir J, Steinberg AD (1990) A study of fatigue in systemic lupus erythematosus. J Rheumatol 17:1450-1452
4. Tench CM, McCurdie I, White PD, D'Cruz DP (2000) The prevalence of fatigue in systemic lupus erythematosus. Rheumatology 39:1249-1254
5. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G (2002) Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 29:482-486
6. Comi G, Leocani L, Rossi P, Colombo B (2001) Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 248:174-179
7. Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer [Suppl] 92:1684-1688
8. Krupp LB, Pollina DA (1996) Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 9:456-460
9. Kelley KW, Hutchison K, French R et al (1997) Central interleukin-1 receptors as mediators of sickness. In: Moore PM, Lahita RG (eds) Neuropsychiatric manifestations of systemic lupus erythematosus. Ann N Y Acad Sci 823:234-246
10. Rinehart J, Hersh E, Issell B, Triozzi P, Buhles W, Neidhart J (1997) Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology Group Study 8940. Cancer Invest 15:403-410
11. Farrar WL, Killian PL, Ruff MR, Hill JM, Pert CB (1987) Visualization and characterization of interleukin-1 receptors in brain. Endocrinology 139:459-463
12. Konsman JP, Blond D, Vigues S (2000) Neurobiology of interleukin-1 receptors: getting the message. Eur Cytokine Netw 11:699-702
13. Carrié A, Jun L, Bienvenu T et al (1999) A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nature Genetics 23:25-31
14. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
15. http://www.das-score.n1/www.das-score.n1/DAS-frame-1.htm
16. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121-1123
17. Bresnihan B (2001) The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Bio Drugs 15:87-97
18. Guyatt GH, Townsend M, Berman LB, Keller JL (1987) A comparison of Likert and visual analogue scales for measuring change in function. J Chron Dis 40:1129-1133
19. Wang B, Gladman DD, Urowitz MB (1998) Fatigue in lupus is not correlated with disease activity. J Rheumatol 25:892-895
20. Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB (1999) Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum 58:379-381
21. Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI (2003) Fatigue in patients with systemic lupus erythematosus: the psychosocial aspects. J Rheumatol 30:283-287
22. Schiller JH, Storer BE, Witt PL et al (1991) Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly. Cancer Res 51:1651-1658
23. Layé S, Lundkvist J, Bartfai T (1999) Cytokines in the brain. In: Thèze J (ed) The cytokine network and immune functions. Oxford University Press, New York, pp 262-269
24. Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M (1993) Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 8:196-200
25. Riemsa RP, Rasker JJ, Taal E, Griep EN, Wouters JMGW, Wiegman O (1998) Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 37:1042-1046
26. Belza BL (1995) Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 22:639-643
27. Giovannoni G, Thompson AJ, Miller DH, Thompson EJ (2001) Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 57:676-681
28. Bakshi R, Miletich RS, Henschel K et al (1999) Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 53:1151-1153